A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
Subjects who qualify will receive single agent lenalidomide once daily on days 1-21 of 28 day
cycles. Subjects will continue until disease progression is documented.